Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Philip T. Cagle

Faculty

Philip T. Cagle, MD

Philip T. Cagle, MD

Medical Director, Pulmonary Pathology
Department of Pathology and Genomic Medicine
The Methodist Hospital Physician Organization
Senior Member
Houston Methodist Research Institute
Professor of Pathology and Laboratory Medicine
Weill Cornell Medical College of Cornell University

6565 Fannin Street, Suite M227
Houston, Texas 77030
Phone: 713-441-6478
Email: pcagle@houstonmethodist.org

Biography

Dr. Cagle received his MD degree from the University of Tennessee College of Medicine in Memphis in 1981. After completing his pathology residency at the Baylor College of Medicine in Houston, Texas, he completed a fellowship in pulmonary pathology research at the University of British Columbia in Vancouver. Dr. Cagle joined the faculty at the Baylor College of Medicine as an instructor in the Department of Pathology in 1984. He became a full professor there in 2000. Dr. Cagle joined Houston Methodist Hospital as an attending pathologist in 1987, and became the director of Pulmonary Pathology at Houston Methodist in 2004. In addition to being editor-in-chief of Archives of Pathology and Laboratory Medicine, Dr. Cagle is on the editorial boards of CAP Today and Human Pathology. Dr. Cagle served as co-chair and co-author of the College of American Pathologists (CAP) Lung Cancer Biomarker Guidelines and chaired the CAP Lung Cancer Biomarker Reporting Template Workgroup. Dr. Cagle is a recipient of the CAP Distinguished Patient Care Award, the CAP Pathologist of the Year Award (2013), and the Texas Society of Pathologists John J. Andujar, MD Citation of Merit Award. He is the author of over 150 peer-reviewed papers, editor of 15 textbooks, editor of two electronic books, and series editor for 3 book series. He joined the faculty at the Weill Cornell Medical College in 2005.

Dr. Cagle is a general surgical pathologist with subspecialty interest in pulmonary pathology. Dr. Cagle's research interests focus on predictive and prognostic biomarkers in lung cancer.

Representative Recent Publications

  • Zhang W, McQuitty EB, Olsen R, Fan H, Hendrickson H, Tio FO, Newton K, Cagle P, Jagirdar J. EGFR Mutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma. Arch Pathol Lab Med. 2013 Aug 12. [Epub ahead of print]
  • Cagle PT, Sholl LM, Lindeman NI, Alsabeh R, Divaris DX, Foulis P, Lee G, Neal JW, Nowak JA, Yu PP. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non-Small Cell Carcinoma of the Lung. Arch Pathol Lab Med. 2013 Jun 28. [Epub ahead of print]
  • McQuitty E, Zhang W, Hendrickson H, Tio FO, Jagirdar J, Olsen R, Cagle P. Lung Adenocarcinoma Biomarker Incidence in Hispanic Versus Non-Hispanic White Patients. Arch Pathol Lab Med. 2013 Jun 26. [Epub ahead of print].
  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013 Jul;15(4):415-53.
  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013 Jul;8(7):823-59.
  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013 Jun;137(6):828-860.
  • Tochigi N, Attanoos R, Chirieac LR, Allen TC, Cagle PT, Dacic S. p16 Deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med. 2013 May;137(5):632-6.
  • Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson A, Roggli V, Travis WD, Wick M. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013 May;137(5):647-67.
  • Cagle PT, Olsen RJ. The proposed new classification of pulmonary adenocarcinoma and the conservation of small tissue samples for testing. Arch Pathol Lab Med. 2013 Apr;137(4):453-4.
  • Cagle PT. The new American Cancer Society Lung Cancer Screening guidelines and the role of the pathologist. Arch Pathol Lab Med. 2013 Apr;137(4):451.
  • Cagle PT, Zhai QJ, Murphy L, Low PS. Folate Receptor in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: Potential Target for Folate-Linked Therapeutic Agents. Arch Pathol Lab Med. 2013 Feb;137(2):241-4.
  • Cornejo KM, Shi M, Akalin A, Uy K, Cagle PT, Fraire AE. Pulmonary papillary adenoma: a case report and review of the literature. J Bronchology Interv Pulmonol. 2013 Jan;20(1):52-7.
  • Brown AF, Sirohi D, Fukuoka J, Cagle P, Policarpio-Nicolas M, Tacha D, Jagirdar J. Tissue-Preserving Antibody Cocktails to Differentiate Primary Squamous Cell Carcinoma, Adenocarcinoma, and Small Cell Carcinoma of Lung. Arch Pathol Lab Med. 2013 Jan 4. [Epub ahead of print]
  • Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, Graziano P, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD, Funkhouser WK. Validation of Interobserver Agreement in Lung Cancer Assessment Hematoxylin-Eosin Diagnostic Reproducibility for Non-Small Cell Lung Cancer-The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. Arch Pathol Lab Med. 2013 Jan;137(1):32-40.
  • Chandra D, Wise RA, Kulkarni HS, Benzo RP, Criner G, Make B, Slivka WA, Ries AL, Reilly JJ, Martinez FJ, Sciurba FC; NETT Research Group, including Cagle P. Optimizing the 6-min walk test as a measure of exercise capacity in COPD. Chest. 2012 Dec;142(6):1545-52.
  • Cagle PT, Olsen RJ. Verifying the Role of Surgical Pathologists in the Precision Medicine of Lung Cancer. Arch Pathol Lab Med. 2012 Dec 31. [Epub ahead of print]
  • Gao L, Wang Z, Li F, Hammoudi AA, Thrall MJ, Cagle PT, Wong ST. Differential diagnosis of lung carcinoma with coherent anti-Stokes Raman scattering imaging. Arch Pathol Lab Med. 2012 Dec;136(12):1502-10.
  • Cagle PT, Allen TC. Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med. 2012 Dec;136(12):1482-91.
  • Cagle PT. Evolving frontlines in the diagnosis and treatment of pulmonary diseases. Arch Pathol Lab Med. 2012 Dec;136(12):1476-7.
  • Cagle PT, Myers J. Precision medicine for lung cancer: role of the surgical pathologist. Arch Pathol Lab Med. 2012 Oct;136(10):1186-9.
  • Cagle PT. The transformation of pathology: proceedings of the Houston Lung Symposium. Arch Pathol Lab Med. 2012 Oct;136(10):1184-5.
  • Oviedo SP, Cagle PT. Diffuse malignant mesothelioma. Arch Pathol Lab Med. 2012 Aug;136(8):882-8.
  • Gao L, Hammoudi AA, Li F, Thrall MJ, Cagle PT, Chen Y, Yang J, Xia X, Fan Y, Massoud Y, Wang Z, Wong ST. Differential diagnosis of lung carcinoma with three-dimensional quantitative molecular vibrational imaging. J Biomed Opt. 2012 Jun;17(6):066017.
  • Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012 May;136(5):504-9.
  • Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012 Feb;136(2):163-71.
  • Churg A, Cagle PT, Colby TV, Corson JM, Gibbs AR, Hammar S, Ordonez N, Roggli VL, Tazelaar HD, Travis WD, Wick M; from the US-Canadian Mesothelioma Reference Panel. The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas. Am J Surg Pathol. 2011 Dec;35(12):1823-29.
  • Gao L, Li F, Thrall MJ, Yang Y, Xing J, Hammoudi AA, Zhao H, Massoud Y, Cagle PT, Fan Y, Wong KK, Wang Z, Wong ST. On-the-spot lung cancer differential diagnosis by label-free, molecular vibrational imaging and knowledge-based classification. J Biomed Opt. 2011 Sep;16(9):096004.
  • Cagle PT, Dacic S, Allen TC. Genomic pathology: challenges for implementation. Arch Pathol Lab Med. 2011 Aug;135(8):967-8.
  • Fudala R, Allen TC, Krupa A, Cagle PT, Nash S, Gryczynski Z, Gryczynski I, Kurdowska AK. Increased levels of nuclear factor ?B and Fos-related antigen 1 in lung tissues from patients with acute respiratory distress syndrome. Arch Pathol Lab Med. 2011 May;135(5):647-54.
  • Cagle PT, Dacic S. Lung cancer and the future of pathology. Arch Pathol Lab Med. 2011 Mar;135(3):293-5.
  • Cagle PT, Allen TC. Pathology of the pleura: what the pulmonologists need to know. Respirology. 2011 Apr;16(3):430-8.
  • Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA, Sciurba F; National Emphysema Treatment Trial (NETT) Research Group. The minimal important difference of exercise tests in severe COPD. Eur Respir J. 2011 Apr;37(4):784-90.
  • Cagle PT. Pathologists as leaders, innovators, and devoted physicians: special section on pathology in resource-poor nations. Arch Pathol Lab Med. 2011 Feb;135(2):170.
  • Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011 Jan;135(1):110-6.
  • Lewis AL, Truong LD, Cagle P, Qihui Zhai. Benign salivary gland tissue inclusion in a pulmonary hilar lymph node from a patient with invasive well-differentiated adenocarcinoma of the lung: a potential misinterpretation for the staging of carcinoma. Int J Surg Pathol. 2011 Jun;19(3):382-5.